Search Results - "Hsu, Vivien M."

2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative by Hoogen, Frank, Khanna, Dinesh, Fransen, Jaap, Johnson, Sindhu R., Baron, Murray, Tyndall, Alan, Matucci‐Cerinic, Marco, Naden, Raymond P., Medsger, Thomas A., Carreira, Patricia E., Riemekasten, Gabriela, Clements, Philip J., Denton, Christopher P., Distler, Oliver, Allanore, Yannick, Furst, Daniel E., Gabrielli, Armando, Mayes, Maureen D., Laar, Jacob M., Seibold, James R., Czirjak, Laszlo, Steen, Virginia D., Inanc, Murat, Kowal‐Bielecka, Otylia, Müller‐Ladner, Ulf, Valentini, Gabriele, Veale, Douglas J., Vonk, Madelon C., Walker, Ulrich A., Chung, Lorinda, Collier, David H., Csuka, Mary Ellen, Fessler, Barri J., Guiducci, Serena, Herrick, Ariane, Hsu, Vivien M., Jimenez, Sergio, Kahaleh, Bashar, Merkel, Peter A., Sierakowski, Stanislav, Silver, Richard M., Simms, Robert W., Varga, John, Pope, Janet E.

“…Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis (SSc) lack sensitivity for early SSc and limited…”
Get full text

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial by Tashkin, Donald P, Prof, Roth, Michael D, Prof, Clements, Philip J, Prof, Furst, Daniel E, Prof, Khanna, Dinesh, Prof, Kleerup, Eric C, Prof, Goldin, Jonathan, Prof, Arriola, Edgar, PharmD, Volkmann, Elizabeth R, MD, Kafaja, Suzanne, MD, Silver, Richard, Prof, Steen, Virginia, Prof, Strange, Charlie, Prof, Wise, Robert, Prof, Wigley, Fredrick, Prof, Mayes, Maureen, Prof, Riley, David J, Prof, Hussain, Sabiha, MD, Assassi, Shervin, MD, Hsu, Vivien M, MD, Patel, Bela, MD, Phillips, Kristine, MD, Martinez, Fernando, Prof, Golden, Jeffrey, Prof, Connolly, M Kari, Prof, Varga, John, Prof, Dematte, Jane, Prof, Hinchcliff, Monique E, MD, Fischer, Aryeh, MD, Swigris, Jeffrey, DO, Meehan, Richard, MD, Theodore, Arthur, Prof, Simms, Robert, Prof, Volkov, Suncica, MD, Schraufnagel, Dean E, Prof, Scholand, Mary Beth, MD, Frech, Tracy, MD, Molitor, Jerry A, Prof, Highland, Kristin, MD, Read, Charles A, Prof, Fritzler, Marvin J, Prof, Kim, Grace Hyun J, PhD, Tseng, Chi-Hong, PhD, Elashoff, Robert M, Prof

“…Summary Background 12 months of oral cyclophosphamide has been shown to alter the progression of scleroderma-related interstitial lung disease when compared…”
Get full text

Expert consensus on the management of systemic sclerosis-associated interstitial lung disease by Rahaghi, Franck F, Hsu, Vivien M, Kaner, Robert J, Mayes, Maureen D, Rosas, Ivan O, Saggar, Rajan, Steen, Virginia D, Strek, Mary E, Bernstein, Elana J, Bhatt, Nitin, Castelino, Flavia V, Chung, Lorinda, Domsic, Robyn T, Flaherty, Kevin R, Gupta, Nishant, Kahaleh, Bashar, Martinez, Fernando J, Morrow, Lee E, Moua, Teng, Patel, Nina, Shlobin, Oksana A, Southern, Brian D, Volkmann, Elizabeth R, Khanna, Dinesh

“…Systemic sclerosis (SSc) is a rare, complex, connective tissue disorder. Interstitial lung disease (ILD) is common in SSc, occurring in 35-52% of patients and…”
Get full text

Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience by Castellví, Ivan, Elhai, Muriel, Bruni, Cosimo, Airò, Paolo, Jordan, Suzana, Beretta, Lorenzo, Codullo, Veronica, Montecucco, Carlo Maurizio, Bokarewa, Maria, Iannonne, Florenzo, Balbir, Alexandra, Hsu, Vivien M., Distler, Oliver, Matucci-Cerinic, Marco, Allanore, Yannick

“…To analyze the safety and effectiveness of abatacept (ABA) given in routine care to patients with systemic sclerosis (SSc). Retrospective multicenter…”
Get full text

Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization by HSU, Vivien M, MOREYRA, Abel E, WILSON, Alan C, SHINNAR, Meir, SHINDLER, Daniel M, WILSON, Julianne E, DESAI, Ami, SEIBOLD, James R

“…OBJECTIVE: Pulmonary hypertension (PH) is an ominous complication in patients with scleroderma (systemic sclerosis, SSc). We compared noninvasive assessment of…”
Get full text

Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study by Hsu, Vivien M., MD, Chung, Lorinda, MD, MS, Hummers, Laura K., MD, Wigley, Fredrick, MD, Simms, Robert, MD, Bolster, Marcy, MD, Silver, Rick, MD, Fischer, Aryeh, MD, Hinchcliff, Monique E., MD, MS, Varga, John, MD, Goldberg, Avram Z., MD, Derk, Chris T., MD, Schiopu, Elena, MD, Khanna, Dinesh, MD, Shapiro, Lee S., MD, Domsic, Robyn T., MD, Medsger, Thomas, MD, Mayes, Maureen D., MD, MPH, Furst, Daniel, MD, Csuka, Mary E., MD, Molitor, Jerry A., MD, Alkassab, Firas, MD, Steen, Virginia D., MD

“…Abstract Objectives PHAROS registry is a prospective longitudinal cohort study to understand the natural history of pulmonary hypertension (PH) in systemic…”
Get full text

Survival in systemic sclerosis–pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry by Hinchcliff, Monique, MD, MS, Khanna, Saira, BA, Hsu, Vivien M., MD, Lee, Jungwha, PhD, MPH, Almagor, Orit, MA, Chang, Rowland W., MD, MPH, Steen, Virginia, MD, Chung, Lorinda, MD, MS

“…Abstract Objective To determine the association between serum autoantibodies and survival in patients with incident systemic sclerosis (SSc)–pulmonary arterial…”
Get full text

Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud's Phenomenon Secondary to Systemic Sclerosis by SCHIOPU, Elena, HSU, Vivien M, IMPENS, Ann J, ROTHMAN, Jennifer A, MCCLOSKEY, Deborah A, WILSON, Julianne E, PHILLIPS, Kristine, SEIBOLD, James R

“…Raynaud's phenomenon (RP) is an important clinical feature of systemic sclerosis (SSc) for which consistently effective therapies are lacking. The study was…”
Get full text

Echocardiogram: The GPS to GPA’s Heart (Granulomatosis with Polyangiitis) by Borham, Amanda, Hsu, Vivien M., Alikhan, Mariam, Parmar, Manpreet K.

“…Granulomatosis with polyangiitis (GPA) is a rare ANCA-associated necrotizing granulomatous vasculitis affecting small- to medium-sized vessels. Common…”
Get full text

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative by van den Hoogen, Frank, Khanna, Dinesh, Fransen, Jaap, Johnson, Sindhu R, Baron, Murray, Tyndall, Alan, Matucci-Cerinic, Marco, Naden, Raymond P, Medsger, Jr, Thomas A, Carreira, Patricia E, Riemekasten, Gabriela, Clements, Philip J, Denton, Christopher P, Distler, Oliver, Allanore, Yannick, Furst, Daniel E, Gabrielli, Armando, Mayes, Maureen D, van Laar, Jacob M, Seibold, James R, Czirjak, Laszlo, Steen, Virginia D, Inanc, Murat, Kowal-Bielecka, Otylia, Müller-Ladner, Ulf, Valentini, Gabriele, Veale, Douglas J, Vonk, Madelon C, Walker, Ulrich A, Chung, Lorinda, Collier, David H, Ellen Csuka, Mary, Fessler, Barri J, Guiducci, Serena, Herrick, Ariane, Hsu, Vivien M, Jimenez, Sergio, Kahaleh, Bashar, Merkel, Peter A, Sierakowski, Stanislav, Silver, Richard M, Simms, Robert W, Varga, John, Pope, Janet E

“…The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc…”
Get more information

Inorganic pyrophosphate is reduced in patients with systemic sclerosis by Hsu, Vivien M, Kozák, Eszter, Li, Qiaoli, Bocskai, Márta, Schlesinger, Naomi, Rosenthal, Ann, McClure, Scott T, Kovács, László, Bálint, László, Szamosi, Szilvia, Szücs, Gabriella, Carns, Mary, Aren, Kathleen, Goldberg, Isaac, Váradi, András, Varga, John

“…Abstract Objective The pathogenesis of calcinosis cutis, a disabling complication of SSc, is poorly understood and effective treatments are lacking. Inorganic…”
Get full text

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial by Matucci-Cerinic, Marco, Denton, Christopher P, Furst, Daniel E, Mayes, Maureen D, Hsu, Vivien M, Carpentier, Patrick, Wigley, Fredrick M, Black, Carol M, Fessler, Barri J, Merkel, Peter A, Pope, Janet E, Sweiss, Nadera J, Doyle, Mittie K, Hellmich, Bernhard, Medsger, Jr, Thomas A, Morganti, Adele, Kramer, Fabrice, Korn, Joseph H, Seibold, James R

“…Ischaemic digital ulcers (DUs) are common in patients with systemic sclerosis (SSc) and are a cause of disease-related morbidity. In an earlier trial,…”
Get more information

Sex influence on outcomes of patients with systemic sclerosis–associated interstitial lung disease: a EUSTAR database analysis by Campochiaro, Corrado, Hoffmann-Vold, Anna-Maria, Avouac, Jerome, Henes, Jörg, de Vries-Bouwstra, Jeska, Smith, Vanessa, Siegert, Elise, Airò, Paolo, Oksel, Fahrettin, Pellerito, Raffaele, Vanthuyne, Marie, Pozzi, Maria Rosa, Inanc, Murat, Sibilia, Jean, Gabrielli, Armando, Distler, Oliver, Allanore, Yannick

“…Abstract Objective Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc) patients. We aimed to…”
Get full text

Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study by Hsu, Vivien M, Denton, Christopher P, Domsic, Robyn T, Furst, Daniel E, Rischmueller, Maureen, Stanislav, Marina, Steen, Virginia D, Distler, Jörg H W, Korish, Shimon, Cooper, Alyse, Choi, Suktae, Schafer, Peter H, Horan, Gerald, Hough, Douglas R

“…To evaluate the safety and efficacy of pomalidomide (POM) on forced vital capacity (FVC), modified Rodnan skin score (mRSS), and gastrointestinal (GI)…”
Get full text

Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment by Bruni, Cosimo, Heidenreich, Sebastian, Duenas, Ashley, Hoffmann-Vold, Anna-Maria, Gabrielli, Armando, Allanore, Yannick, Chatelus, Emmanuel, Distler, Jörg H W, Hachulla, Eric, Hsu, Vivien M, Hunzelmann, Nicolas, Khanna, Dinesh, Truchetet, Marie-Elise, Walker, Ulrich A, Alves, Margarida, Schoof, Nils, Saketkoo, Lesley Ann, Distler, Oliver

“…Abstract Objectives Treatments for SSc-associated interstitial lung disease (SSc-ILD) differ in attributes, i.e. mode of administration, adverse events (AEs)…”
Get full text

Cyclophosphamide versus Placebo in Scleroderma Lung Disease by Tashkin, Donald P, Elashoff, Robert, Clements, Philip J, Goldin, Jonathan, Roth, Michael D, Furst, Daniel E, Arriola, Edgar, Silver, Richard, Strange, Charlie, Bolster, Marcy, Seibold, James R, Riley, David J, Hsu, Vivien M, Varga, John, Schraufnagel, Dean E, Theodore, Arthur, Simms, Robert, Wise, Robert, Wigley, Fredrick, White, Barbara, Steen, Virginia, Read, Charles, Mayes, Maureen, Parsley, Ed, Mubarak, Kamal, Connolly, M. Kari, Golden, Jeffrey, Olman, Mitchell, Fessler, Barri, Rothfield, Naomi, Metersky, Mark

“…Interstitial lung disease is a common complication of systemic sclerosis, but there is no widely accepted treatment. In this randomized, placebo-controlled…”
Get full text

Patient Experience of Systemic Sclerosis-Related Calcinosis: An International Study Informing Clinical Trials, Practice, and the Development of the Mawdsley Calcinosis Questionnaire by Saketkoo, Lesley Ann, Gordon, Jessica K, Fligelstone, Kim, Mawdsley, Anne, Chaudhry, Humza A, Valenzuela, Antonia, Christensen, Angela, Khalique, Samara M, Jensen, Kelly, Weinmann, Sophia C, Busman, Evan, Chung, Lorinda, Hsu, Vivien M, Russell, Anne-Marie, Steen, Virginia D

“…Systemic sclerosis (SSc) -related calcinosis can be a debilitating, constantly painful, poorly understood vascular complication of calcium hydroxyapatite…”
Get full text

Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry by Hsu, Vivien M, Chung, Lorinda, Hummers, Laura K, Shah, Ami, Simms, Robert, Bolster, Marcy, Hant, Faye N, Silver, Richard M, Fischer, Aryeh, Hinchcliff, Monique E, Varga, John, Goldberg, Avram Z, Derk, Chris T, Schiopu, Elena, Khanna, Dinesh, Shapiro, Lee S, Domsic, Robyn T, Medsger, Thomas, Mayes, Maureen D, Furst, Daniel, Csuka, Mary Ellen, Molitor, Jerry A, Saketkoo, Lesley Ann, Salazar, Christian R, Steen, Virginia D

“…We sought to identify predictors of mortality and cardiopulmonary hospitalizations in patients at risk for pulmonary hypertension (PH) and enrolled in PHAROS,…”
Get full text

Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease by Tashkin, Donald P, Elashoff, Robert, Clements, Philip J, Roth, Michael D, Furst, Daniel E, Silver, Richard M, Goldin, Jonathan, Arriola, Edgar, Strange, Charlie, Bolster, Marcy B, Seibold, James R, Riley, David J, Hsu, Vivien M, Varga, John, Schraufnagel, Dean, Theodore, Arthur, Simms, Robert, Wise, Robert, Wigley, Fred, White, Barbara, Steen, Virginia, Read, Charles, Mayes, Maureen, Parsley, Ed, Mubarak, Kamal, Connolly, M. Kari, Golden, Jeffrey, Olman, Mitchell, Fessler, Barri, Rothfield, Naomi, Metersky, Mark, Khanna, Dinesh, Li, Ning, Li, Gang, Scleroderma Lung Study Research Group

“…The Scleroderma Lung Study enrolled 158 patients with scleroderma-related interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide…”
Get full text

Inclusion body myositis in a patient with RNA polymerase III antibody-positive systemic sclerosis by Vemulapalli, Srikanth, Sharer, Leroy R, Hsu, Vivien M

Get full text